TL;DR: Atorvastatin is not a recognised cause of erectile dysfunction, and the best available evidence suggests it is more likely to improve erectile function than worsen it — particularly in men with cardiovascular disease or high cholesterol. A 2024 pharmacovigilance study identified a reporting signal between atorvastatin and ED, but a meta-analysis of randomised controlled trials found atorvastatin may actually be an effective treatment for ED. The underlying cardiovascular disease being treated is a far more likely explanation.
Atorvastatin is the most commonly prescribed cholesterol-lowering medication in the UK. For many men, it is also the first thing blamed when erectile problems develop — because the timing of starting a new medication and noticing a change feels like cause and effect.
Whether that connection is real is worth examining properly, because the evidence on atorvastatin specifically — not just statins generally — tells a more nuanced and, for most men, more reassuring story than the worry usually implies.
Is Atorvastatin Officially Linked to Erectile Dysfunction?
Sexual dysfunction does appear in the product information for atorvastatin as a possible adverse effect — but this needs careful interpretation.
Drug manufacturers are required to list any adverse event reported during clinical use or post-marketing surveillance, regardless of whether a causal link has been established. The presence of a side effect in a product information leaflet reflects that it has been reported — not that the drug reliably causes it, not that it is common, and not that it has been proven to be the drug’s fault rather than the underlying condition being treated.
The NICE British National Formulary lists erectile dysfunction under the category of uncommon side effects for atorvastatin — meaning it occurs in somewhere between 1 in 100 and 1 in 1,000 users based on reporting. This is a low frequency category, and it does not distinguish between drug-caused ED and ED that would have occurred regardless in a population of men with cardiovascular disease.
There is also the nocebo effect to consider. Men who are told a medication might affect sexual function are measurably more likely to report that it does — even when taking a placebo. This is a well-documented phenomenon in statin research and contributes to the signal without reflecting a genuine pharmacological effect.
What a Major 2024 Study Found About Atorvastatin and ED
The most specific and recent evidence on atorvastatin and ED comes from a comprehensive 2024 analysis published in Frontiers in Pharmacology, which took two approaches simultaneously — one that found a signal and one that did not find causation.
The PMC-published study used real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) database — one of the world’s largest collections of drug adverse event reports. Using multiple statistical methods, the researchers found a significant disproportionality signal between atorvastatin and ED. In plain terms: ED was reported more frequently in association with atorvastatin than would be expected by chance alone.
A pharmacovigilance signal like this is clinically meaningful — it means the association is real enough to warrant investigation. But it does not mean atorvastatin causes ED. Pharmacovigilance data cannot establish causality because it cannot account for confounding — the fact that men taking atorvastatin are, by definition, men with elevated cardiovascular risk, and cardiovascular disease is one of the leading causes of ED.
This is precisely why the same study went further and applied Mendelian randomisation — a method that uses genetic variation as a natural experiment to test causal relationships more robustly. The Mendelian randomisation analysis found no evidence that atorvastatin causes ED. The pharmacovigilance signal is real; the causation is not supported. These two findings can coexist because the signal is explained by confounding — men with high cholesterol and heart disease have more ED, and those men also happen to be on atorvastatin.
The same paper noted that a prospective study comparing rosuvastatin and atorvastatin directly found that atorvastatin increased ED risk while rosuvastatin did not — suggesting possible differences between specific statin types. This finding is worth noting but has not been replicated consistently.
The Evidence That Atorvastatin May Actually Improve Erectile Function
Here is where the story becomes genuinely counterintuitive. Multiple studies — including a meta-analysis of randomised controlled trials — suggest atorvastatin may actually improve erectile function rather than worsen it.
A meta-analysis published in Andrologia in 2022 analysed all published randomised controlled trials examining atorvastatin in the treatment of ED. The conclusion: atorvastatin may be an effective treatment for erectile dysfunction. The biological mechanism is plausible and well-described — atorvastatin activates endothelial nitric oxide synthase (eNOS), increasing nitric oxide production in penile blood vessels and improving the vascular response to sexual arousal.
One of the most striking findings in this literature is that atorvastatin has been shown to improve erectile function in men who had not responded to sildenafil — men whose vascular ED was severe enough that the standard first-line PDE5 inhibitor treatment was insufficient. By improving endothelial function directly, atorvastatin appears to restore enough vascular responsiveness to make sildenafil effective in men for whom it previously was not.
This mechanism makes biological sense. Atorvastatin’s benefits extend beyond simply lowering LDL cholesterol — its pleiotropic effects include reducing arterial inflammation, improving endothelial function throughout the vascular system, and slowing the progression of atherosclerosis. Since erectile function depends on the same vascular responsiveness that these effects restore, the therapeutic benefit on ED in men with significant vascular disease is physiologically coherent.
For most men taking atorvastatin for cardiovascular risk — men with elevated cholesterol, early atherosclerosis, or a history of cardiac events — the drug is more likely to be protecting their erectile function than impairing it.
Why the Cardiovascular Disease Is Almost Certainly the Cause, Not the Atorvastatin
This is the most clinically important point — and it is consistently underappreciated.
Men who are prescribed atorvastatin have it because they have elevated cardiovascular risk. High LDL cholesterol, atherosclerosis, endothelial dysfunction, or a history of cardiac events are the conditions it is prescribed to treat. The NHS confirms that cardiovascular disease, high blood pressure, and high cholesterol are among the most common physical causes of erectile dysfunction — the same conditions atorvastatin treats.
A man who starts atorvastatin at 52 and notices erectile problems at 54 has been accumulating vascular risk factors for decades. The atherosclerosis narrowing his coronary arteries is also narrowing the penile arteries. The endothelial dysfunction reducing blood flow to his heart is reducing blood flow to the corpus cavernosum.
Stopping atorvastatin removes the drug from the equation but leaves the atherosclerosis, the endothelial dysfunction, and the elevated LDL untreated. This is a bad trade for erectile function as well as for cardiovascular health.
Does Atorvastatin Lower Testosterone?
This is a separate and legitimate question. Some research suggests statins may lower total testosterone levels — and testosterone is important for both libido and erectile function.
The evidence here is mixed and atorvastatin-specific data is limited. Some studies show modest reductions in total testosterone in men on statins; others show no significant change. The clinical significance of these findings depends heavily on whether total testosterone or bioavailable testosterone is affected — total testosterone can fall while bioavailable testosterone (the fraction that actually reaches tissues) remains adequate.
A dose-dependent effect of atorvastatin on testosterone has been noted in some studies — higher doses associated with greater reductions. If you are on a high dose of atorvastatin (40mg or 80mg daily) and experiencing symptoms consistent with low testosterone — reduced libido, fatigue, reduced muscle mass, low mood — checking your testosterone level is clinically sensible.
Our private blood tests can check total testosterone, SHBG, and LH alongside a full cardiovascular panel — giving a complete picture of both the hormonal and vascular contributors to erectile function.
What to Do If You Take Atorvastatin and Have ED
Do not stop atorvastatin without speaking to your GP first. The cardiovascular protection it provides is substantial and evidence-based. If the ED is driven by the same vascular disease atorvastatin is treating, stopping it removes the drug and leaves the vascular condition progressing unchecked — which is likely to make the erectile function worse over time, not better.
A proper clinical assessment is the right response. ED in a man on atorvastatin deserves investigation for the following:
Blood pressure — often a direct contributor to ED and modifiable with treatment. Testosterone — if symptoms suggest deficiency, a blood test confirms it. Blood glucose and HbA1c — diabetes is a leading cause of ED and coexists with cardiovascular disease. Full lipid panel — to assess whether cholesterol is adequately controlled and whether atorvastatin is working as it should.
PDE5 inhibitors — sildenafil and tadalafil — are safe to use alongside atorvastatin and are effective first-line treatments for ED in men with cardiovascular disease. There is no clinically significant drug interaction between PDE5 inhibitors and statins.
If there is a genuine clinical suspicion that atorvastatin specifically is contributing, your GP can consider switching to a different statin. The 2024 study noted potential differences between atorvastatin and rosuvastatin — rosuvastatin being associated with less ED signal in at least one prospective study. This is not a definitive reason to switch, but it is a reasonable clinical conversation if other approaches have not helped.
At The Private GP in Birmingham, our private GP consultation covers the full picture — cardiovascular markers, testosterone, and treatment options — with same-day results and no referral needed.
Frequently Asked Questions
Should I stop taking atorvastatin if I think it’s causing ED?
No — not without speaking to your GP first. Atorvastatin provides significant cardiovascular protection, and the ED is more likely caused by the underlying vascular disease than by the drug. A proper assessment will identify what is actually driving the problem.
Is atorvastatin worse for erectile dysfunction than other statins?
One prospective study suggested atorvastatin was associated with more ED risk than rosuvastatin, but this finding has not been consistently replicated. If you have concerns about your specific statin, discuss switching with your GP rather than stopping cholesterol-lowering therapy altogether.
Can I take Viagra or Cialis with atorvastatin?
Yes. PDE5 inhibitors including sildenafil and tadalafil are safe to use alongside atorvastatin with no clinically significant drug interaction. They are among the most studied ED treatments in men with cardiovascular disease and are effective in this population.
How long does it take for atorvastatin to affect erectile function?
If atorvastatin is going to improve erectile function through better endothelial health, this develops gradually over weeks to months as vascular function improves. Any worsening of ED after starting atorvastatin is more likely explained by the natural progression of the underlying cardiovascular disease than by the drug itself.
If atorvastatin improves blood flow, why do some men on it still have ED?
Because ED is multifactorial. Atorvastatin may improve one vascular pathway while other contributors — low testosterone, uncontrolled blood pressure, diabetes, psychological factors, or other medications — continue to drive ED independently. Addressing one factor does not automatically resolve a problem with multiple causes.